ImmuneOnco Published crystal protein structure of IMM01
On August 31, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced the publication of the crystal protein structure of IMM01. The tittle of the paper is " Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)’’appeared on Molecules. Vol 27, Issue 17. The data reveal the key amino acid site of the interaction between IMM01 and CD47, which is highly consistent with previously published binding site of SIRPα and CD47 (Protein Structure Library Index No. 2JJT). The crystal structure study further confirmed the pharmacological basis of IMM01.
Chairman and founder of ImmuneOnco, Dr. Tian, Wenzhi said:
"I am very pleased to know that the crystal structure data of our core product IMM01 protein has been published in the journal "Molecules". The research results of the IMM01 published in the journal "Molecules" demonstrates its academic and developmental significance. We are focusing on research and development of IMM01 and continue to accelerate clinical development to further explore the efficacy and safety mechanisms of IMM01."
"We are full of confidence in IMM01. We are accelerating the progress of clinical development and industrialization, and actively promoting the clinical research on the combination of IMM01 and other targeted drugs. We are speeding up our steps on the launch of IMM01. We believe that IMM01 will bring good news to cancer patients soon."